

Zydus receives final approval from the USFDA for Clomipramine Hydrochloride Capsules USP

Ahmedabad, 29 December, 2017

Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary of Cadila Healthcare Limited, has received the final approval from the USFDA to market Clomipramine Hydrochloride Capsules USP in strengths of 25 mg, 50 mg and 75 mg. The drug is used to treat obsessive compulsive disorder which is characterized by uncontrollable, re-occurring thoughts (obsessions) and behaviours (compulsions). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
